ATHX - ATHERSYS - MULTISTEM

MultiStem is a stem cell treatment for stroke patients with several other possible uses for other issues like TBI, etc. It's an off the shelf product administered within 36 hours of the stroke that can possibly completely reverse the effects. Currently in stage 3 FDA testing.

The stock is currently trading around $2 per share. It's possible this share could be trading in the ~$150-250 range in the next 2 years if approval is reached. This stock has a great risk reward profile.

This is the moonshot you've been looking for, and it ain't an overnight thing. I don't have a lot of money so I've bought 500 shares and I won't be letting them go for a minimum of three years. Here's hoping everything goes well!

News video on the drug:
youtube.com/watch?v=Ui2WPt9vaDM

Company ticker is ATHX

Attached: multistem-cells.jpg (625x352, 36K)

Other urls found in this thread:

abc30.com/health/stem-cells-extend-stroke-treatment-window/3024501/
vimeo.com/259418414
journals.sagepub.com/doi/abs/10.1111/ijs.12065
athersys.com/clinical-programs/overview
athersys.com/news-releases/news-release-details/one-year-results-phase-2-stroke-study-multistemr-cell-therapy
clinicaltrials.gov/ct2/show/NCT01436487
twitter.com/NSFWRedditGif

abc30.com/health/stem-cells-extend-stroke-treatment-window/3024501/

"PORTLAND, Ore. (KFSN) -- Nearly 800,000 people have strokes every year in America. The best treatment, tPA (tissue plasminogen activator), has to be given within three hours, and doctors estimate only five percent of patients can make that window. A new treatment that is now in clinical trial could give patients precious additional time.

Sharon Thomas is back at work like nothing was ever wrong. But four years ago, she had a stroke.

"At that time, I couldn't read, write, swallow or speak," Thomas told Ivanhoe.

She was helicoptered to OHSU and the care of Wayne Clark, MD, Director, Oregon Stroke Center, Oregon Health & Science University. He asked if she wanted to be part of a trial for a stem cell treatment that might help her recover. (Read Full Interview)

"What this does, the stem cells are from very, very young cells, and they bathe the brain in this environment that makes it act like it's young again," explained Dr. Clark.

The stem cells also turn off the inflammatory response sent by the spleen to the brain. The bone marrow-derived stem cells come from a donor and are multiplied in a lab.

Doctor Clark continued, "It can be easily stored in a refrigerator, and mixed up quickly, and given by IV. So no specialized facilities will have to be ... and a 36 hour window, so it could really allow a lot of patients to potentially benefit."

Sharon made a significant recovery, like 70 percent of patients in the multistem trial. She credits it with giving her an edge.

Thomas said, "Every day it got better, and my mantra was, 'every day is a good day,' because I'm still here, I'm still improving."

And she hopes more stroke patients have access to MultiStem."

Check this video out this is insane:
vimeo.com/259418414

Attached: Capture.png (829x516, 933K)

Phoneposting, so keeping it short.
AMDA - Amedica
Another stock you should look into to get the bottom since they own the future of next gen implants.

We going to make it

I think so, it appears this will be the standard of care for stroke following approval.

Attached: 57F2A018-C106-41D2-8015-C9DA3A93669E.jpg (768x1024, 131K)

Are you just shilling your bags? Gah, I hope not!

This was a PnD back it the day. How heavy are those bags bud?

I'm holding these 'bags' for a minimum of 3 more years. I don't expect significant gains for about 1.5-2 years

Can you elaborate?